摘要
骨质疏松症是一种以骨量减少,骨组织破坏为特征而导致骨脆性增加并易于骨折的全身性骨骼疾病。本文从作用机制出发,综述首个开发上市的具有抑制破骨细胞吸收和促进骨形成双重作用的新药雷奈酸锶,评价其用于治疗绝经后骨质疏松症的临床安全性和有效性。
Osteoporosis is defined as a skeletal disorder characterized by bone loss with a deterioration of bone issues and a propensity for a fragility fracture.Based on the mechanism,this review describes strontium ranelate as a dual mode of action,while simultaneouly increase bone formation and decrease bone resorption,and evaluatas its safety and efficacy in postmenopausal osteoporsis treatment.
出处
《世界临床药物》
CAS
2011年第11期641-645,共5页
World Clinical Drug
